Onconova Therapeutics, Inc. (ONTX) Stock Skyrockets Following Reverse Stock Split
Onconova Therapeutics, Inc. (ONTX) stock prices were down by a substantial 21.08% as of the market closing on May 20th, 2021, bringing the price per share down to USD$0.73 at the end of the trading day. Subsequent pre-market fluctuations saw the price skyrocket by a monumental 1235.62%, bringing the price per share up to USD$9.69. […]
BioLineRx Ltd. (BLRX) Stock Floats Back Down After Skyrocketing from Success of GENESIS Trial
BioLineRx Ltd. (BLRX) stock prices were down by 3.38% as of the market closing on May 7th, 2021, bringing the price per share down to USD$3.72. Subsequent pre-market fluctuations saw the price fall by another 4.30%, bringing it to USD$3.56. Phase 3 GENESIS Trial The achieving of top-line results by BLRX for their GENESIS Phase […]
Orphazyme A/S (ORPH) Stock Plummeting After Failure of ORAIALS-01 Trial Announced
Orphazyme A/S (ORPH) stock prices plummeted by 27.77% after the market opened on May 7th, 2021, bringing the price per share tumbling down to USD$6.12 after the commencing of the trading day. ORAIALS-01 Ends in Failure The company announced on May 7th, 2021 that the ORAIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) […]
Epizyme, Inc. (EPZM) Stock Experiences Volatility Following Disclosure of Q1 2021 Financial Reports
Epizyme, Inc. (EPZM) stock prices were down by 9.44% as of the market closing on May 6th 2021, bringing the price per share down to USD$6.81 at the end of the trading day. Subsequent current-market fluctuations have seen the stock rally by 20%, bringing it up to USD$8.17. Financial Reports Indicate Strong Growth The first […]
Clovis Oncology, Inc. (CLVS) Stock Trending Up Following Disclosure of Promising Q1 2021 Financial Reports
Clovis Oncology, Inc. (CLVS) stock prices were up a promising 8.89% shortly after the trading day commenced on May 5th, 2021, bringing the price per share up to USD$6.00. Comparative Decrease in Revenue CLVS reported USD$38.1 million in global net product revenues derived from the company’s flagship Rubraca in the first quarter of the fiscal […]
BioLineRX Ltd (BLRX) Stock Skyrockets Following Immense Success of Phase 3 GENESIS Clinical Trial
BioLineRx Ltd. (BLRX) stock prices skyrocketed by 52.98% as of market close on May 3rd 2021, bringing the price per share up to USD$4.88 at the end of the trading day. Subsequent pre-market fluctuations have seen the stock surge another 16.6% to hit USD$5.69. Phase 3 GENESIS trial BLRX announced on May 4th, 2021 the […]
